Logo
x

Search

Subscribe Now

China

New Drug Designations - April 2024

New Drug Designations - April 2024

  • May 30, 2024
Innovent Entered into a Collaboration Agreement with NeoCura to Evaluate Sintilimab + NEO_PLIN2101 for Cancer in China

Innovent Entered into a Collaboration Agreement with NeoCura to Evaluate Sintilimab + NEO_PLIN2101 for Cancer in China

  • October 28, 2021
Hutchmed Initiates P-III ESLIM-01 Trial of HMPL-523 for the Treatment of Immune Thrombocytopenia in China

Hutchmed Initiates P-III ESLIM-01 Trial of HMPL-523 for the Treatment of Immune Thrombocytopenia in China

  • October 28, 2021
AstraZeneca and Hutchmed Initiate P-III SANOVO Trial for Orpathys (savolitinib) + Tagrisso (osimertinib) as a 1L Therapy for Non-small Cell Lung Cancer in China

AstraZeneca and Hutchmed Initiate P-III SANOVO Trial for Orpathys (savolitinib) + Tagrisso (osimertinib) as a 1L Therapy for Non-s...

  • September 9, 2021
BeiGene Reports NMPA's Acceptance of sBLA for Tislelizumab (BGB-A317) to Treat Nasopharyngeal Cancer in China

BeiGene Reports NMPA's Acceptance of sBLA for Tislelizumab (BGB-A317) to Treat Nasopharyngeal Cancer in China

  • August 23, 2021
Novartis' Cosentyx (secukinumab) Receives the NMPA's Approval for the Treatment of Pediatric Psoriasis in China

Novartis' Cosentyx (secukinumab) Receives the NMPA's Approval for the Treatment of Pediatric Psoriasis in China

  • August 17, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.